NAD+: Labeling Standards and Cross-Border Compliance

Executive Summary

Dietary supplements related to nicotinamide adenine dinucleotide (NAD+) have seen sustained growth in distribution across the, mainland, Hong Kong, Macau, Taiwanese, and North American markets. Around this ingredient category, consumers, procurement professionals, and importers consistently encounter three core areas of confusion: what molecule the quantity figure on a product label actually refers to; where substantive differences in labeling requirements exist across jurisdictions; and how to evaluate compliance and traceability when sourcing cross-border. This paper addresses each dimension in turn — the technical logic behind ingredient quantity labeling, labeling regulatory requirements in Japan and key target markets, and cross-border compliance considerations — without making any medical claims or statements of therapeutic effect. It is intended solely as a structured reference for verifiable labeling dimensions.

---

I. Labeling Logic for NAD+ Precursor Ingredients: Which Molecule Is Being Labeled?

1.1 What Is Actually in These Products Is Not NAD+ Itself

The vast majority of supplements marketed as "NAD+" products contain, as their active ingredient, a precursor molecule to NAD+ — not NAD+ itself. The principal precursors include:

• NMN (Nicotinamide Mononucleotide)
• NR (Nicotinamide Riboside)
• Niacin and Nicotinamide (Niacinamide)

NMN and NR are comparatively newer commercial ingredients, whereas niacin and nicotinamide have decades of use history and well-established regulatory recognition in most jurisdictions. Given differences in cost and ingredient availability, the choice of precursor varies considerably across product tiers.

1.2 Two Primary Quantity Labeling Conventions

Current product labeling practice follows two parallel conventions that consumers must be able to distinguish:

Convention A: Labeled quantity refers to the actual input amount of the precursor ingredient

For example, "NMN 250 mg per capsule" — here, 250 mg refers to the weight of the NMN ingredient itself and has no direct conversion relationship to the amount of NAD+ ultimately produced through in vivo metabolism. This is the predominant labeling approach in the market and is consistent with the basic requirements of Japan's Food Labeling Act for "ingredient name and quantity" disclosure.

Convention B: Quantity expressed as a "NAD+ equivalent" or "effective equivalent"

Some brands state an estimated "equivalent to NAD+ X mg" value in non-mandatory fields such as promotional pages or product descriptions. Such conversions carry significant scientific uncertainty. Under Japan's Food Labeling Act, if such a converted figure appears in the mandatory nutrition information panel, it must be supported by a verifiable calculation basis; otherwise it may constitute a misleading representation.

Practical guidance: When comparing products, consumers should use the actual input quantity of the precursor ingredient (mg per capsule or per serving) as the baseline unit, and avoid being misled by "NAD+ equivalent" conversion figures.

1.3 Transparency in Purity and Specification Labeling

Beyond total input quantity, high-transparency products typically disclose the following on the label or in supplementary documentation (third-party test reports, Certificate of Analysis / COA):

• Purity percentage of the precursor ingredient (e.g., "NMN ≥98%")
• Crystal form or salt form (for NMN, these affect stability and solubility)
• Batch number and manufacturing date, for traceability purposes

Japan's JHNFA (Japan Health and Nutrition Food Association) GMP certification system requires certified facilities to maintain complete records covering incoming material inspection, in-process inspection, and finished product inspection. Certification numbers are verifiable in the JHNFA official database. As one example, certification number 34225 represents facility-level manufacturing practice certification — not an endorsement of any particular ingredient quantity — and the two should not be conflated.

---

II. Japan's Labeling Regulatory Framework

2.1 Core Requirements of the Food Labeling Act (Food Labeling Standards)

Japan's Food Labeling Act (in force since 2015, consolidating the Food Sanitation Act, the JAS Act, and the Health Promotion Act) establishes mandatory labeling requirements for all processed foods distributed within Japan:

NMN and NR currently circulate in Japan as general food ingredients (note applicable regulatory developments from around 2021 onward for certain product specifications). When distributed in food form, their ingredient quantity labeling must comply with the framework above, and no medical claims may be made that go beyond the regulatory definition of food.

2.2 Foods with Functional Claims (FFC) and Quantity Labeling

The Consumer Affairs Agency's Foods with Functional Claims (FFC) system permits companies, after notifying the Consumer Affairs Agency and submitting scientific substantiation, to make qualified statements about specific functional ingredients. For products distributed under FFC status:

• The functionally relevant ingredient must be clearly labeled on the package with the amount per recommended daily intake
• The company bears responsibility for that stated quantity and must ensure batch-to-batch consistency
• Notification documents (including systematic reviews, or SRs) are publicly accessible and searchable in the Consumer Affairs Agency database

As of the time of writing, NAD+ precursor ingredients account for a small number of entries in the FFC notification database. Most products circulate as "general foods" or "health foods" — without FFC status, and therefore without either the right to make functional claims or the obligation to meet FFC's strict quantity management requirements. This means that for non-FFC products, batch-to-batch consistency in ingredient quantity relies primarily on corporate self-discipline and GMP systems, rather than on any regulatory mandatory verification mechanism.

2.3 Regulation of Misleading Representations

Japan's Act against Unjustifiable Premiums and Misleading Representations (enforced jointly by the Japan Fair Trade Commission and the Consumer Affairs Agency) prohibits representations that could cause consumers to form an exaggerated or false impression of a product's ingredients, effects, or quality. In the NAD+ product category, regulatory scrutiny focuses on:

• Use of expressions such as "boosts NAD+ levels" or "anti-aging" in non-mandatory fields (advertisement pages, social media, video scripts)
• Describing biochemical changes in the body using specific figures (e.g., "30% increase") without adequate scientific substantiation
• Use of before-and-after imagery that implies improvement in physical function

The Consumer Affairs Agency has progressively intensified enforcement action against misleading representations in health food products since 2019. When evaluating suppliers, a supplier's compliance track record regarding promotional representations is a verifiable risk dimension.

---

III. Labeling Differences Across Key Target Markets

3.1 Mainland China: Dual-Track Registration and Notification System for Health Foods

In mainland China, health foods are regulated by the Measures for the Registration and Notification Administration of Health Foods (promulgated by the State Administration for Market Regulation). NMN-type products have not yet been included in the Health Food Ingredient Catalogue as an approved raw material. Accordingly:

• Products containing NMN may not be lawfully sold within mainland China as health foods
• Identical products imported via the general food pathway may not carry any health function claims on the label or in accompanying materials
• Products entering via the cross-border e-commerce route (bonded warehouse / comprehensive bonded zone model) must comply with the applicable cross-border e-commerce retail import commodity list and associated inspection and quarantine requirements

When consumers purchase Japan-sourced NAD+ products through legitimate cross-border e-commerce platforms, any -language labeling or platform page descriptions containing phrases such as "anti-aging" or "immune-boosting" represent compliance risks on the part of the platform or merchant — they are legally independent of whether the original label is compliant. The two dimensions operate separately under applicable law.

3.2 United States: FDA Dietary Supplement Framework (DSHEA)

The U.S. Dietary Supplement Health and Education Act (DSHEA, 1994) establishes a separate regulatory category for dietary supplements, distinct from drugs and conventional foods. NMN was sold by some companies as a dietary supplement prior to 2022; however, in November 2022 the FDA issued a warning letter concluding that NMN had previously been investigated as a drug ingredient under an Investigational New Drug (IND) application and that, under DSHEA §201(ff)(3)(B)(ii), such an ingredient may not be marketed as a dietary supplement.

This regulatory development has material implications for cross-border sourcing:

• Carrying Japan-sourced NMN products into the United States as personal imports carries the risk of customs seizure
• Compliance postures among U.S.-based e-commerce platforms have diverged

NR (Nicotinamide Riboside) has a comparatively clearer regulatory standing in the United States, having received FDA GRAS (Generally Recognized as Safe) status (GRN No. 635, among others), providing a more stable regulatory foundation for its distribution as a dietary supplement.

3.3 European Union: Novel Food Authorization

The EU Novel Food Regulation (EU 2015/2283) requires that food ingredients with no significant history of consumption in the EU prior to May 15, 1997 must undergo evaluation by the European Food Safety Authority (EFSA) and receive European Commission authorization before they may be placed on the market.

NMN, as a novel food ingredient within the EU definition, has had authorization applications advanced by industry parties; however, as of the time of writing, authorization status remains under review — readers should independently verify the latest developments. The situation for NR is similar: authorization applications have been submitted and certain approvals have been recorded, but the specific scope of any such authorization (applicable product categories, maximum use levels, etc.) must be confirmed against the current EU Novel Food Catalogue.

---

IV. Ingredient Traceability and Third-Party Testing: Compliance Dimensions Beyond the Label

4.1 The Verification Value of the Certificate of Analysis (COA)

The ingredient quantity stated on a label is a self-declaration by the manufacturer. The COA is the critical document for verifying the credibility of that declaration and should cover:

• Measured content: Variance relative to the declared quantity (reputable products typically state a tolerance of ±X%)
• Heavy metal testing: Conformity with limits for lead, mercury, cadmium, and arsenic
• Microbial limits: Total aerobic plate count, coliforms, etc.
• Pesticide residues (for plant-derived ingredients)

Consumers and procurement professionals may request that suppliers provide COAs issued by third-party laboratories holding ISO/IEC 17025 accreditation. Recognized accredited testing bodies within Japan include the Japan Food Research Laboratories (a public interest incorporated foundation), among others; the issuing laboratory information on any test report can be independently verified.

4.2 Scope and Limits of GMP Facility Certification

GMP (Good Manufacturing Practice) certification addresses the manufacturing process management system — not the efficacy or safety of any specific product ingredient. The JHNFA GMP certification scheme requires certified facilities to conform to standards covering raw material management, manufacturing environment controls, inspection records, and non-conforming product disposition; certified facilities are subject to periodic re-evaluation.

To verify whether a specific facility holds JHNFA GMP certification:

• 1. Visit the official JHNFA website and search the list of GMP-certified facilities by certification number or facility name
• 2. Confirm the validity period of the certification
• 3. Confirm that the certification scope covers the product category of interest

Important caveat: GMP certification signifies that the manufacturing system is compliant — it does not imply that the product meets import compliance requirements in the destination country. These two dimensions must be verified independently.

4.3 Stability Data and Shelf-Life Labeling

NAD+ precursor molecules — NMN in particular — are subject to degradation under conditions of elevated temperature and humidity. Compliant labeling must state storage conditions (e.g., "store away from direct sunlight in a cool, dry place") and the expiration date.

A labeled expiration date must be supported by accelerated stability study data. If marketing materials contain representations such as "content will not fall below X% of the labeled value before expiration," the company must be able to substantiate that claim with stability documentation. Temperature and humidity management during cross-border transit is a compliance dimension that importers routinely overlook in product compliance management.

---

V. Actionable Guidance for Consumers

Pre-Purchase Verification Checklist

• 1. Confirm the precursor type and actual input quantity

Check whether the ingredient list clearly states the specific milligram amount of NMN, NR, or another precursor. Do not assess quantity based on the "NAD+" designation alone.

• 2. Verify the manufacturing facility's GMP certification status

Search the official JHNFA database (search "JHNFA GMP certified facilities" to locate the official website entry point), enter the certification number, and confirm that the certification is current and covers the relevant product category.

• 3. Request or download the COA

Prioritize brands that publicly publish batch COAs or provide them on request. Pay particular attention to the variance between measured NMN/NR content and the declared quantity, and to heavy metal test results.

• 4. Identify the product's regulatory classification on the label

Does the product label bear the designation "Food with Functional Claims"? If so, the notification number can be searched in the Consumer Affairs Agency notification database. If not, the product is a general food, and any functional statements represent solely the manufacturer's voluntary representation, without regulatory endorsement.

• 5. Understand the import compliance status in the destination country

- Mainland China: Confirm whether the product falls within covered categories on the cross-border e-commerce commodity list, and whether -language descriptions on platform pages contain non-compliant claims

- United States: Monitor FDA regulatory developments regarding NMN; consult the FDA official website for the latest guidance

- European Union: Check the EU Novel Food Catalogue to confirm the authorization status of the ingredient

• 6. Retain purchase receipts and import records

Cross-border personal carriage or postal import is typically subject to quantity limits, which vary by country. Retaining receipts and declaration records facilitates demonstrating personal-use intent in the event of customs inspection.

• 7. Recognize the limits of functional claims

Regardless of the channel or source of a product description, any language employing terms such as "treats," "prevents," or "reverses" in a medical sense does not meet the compliant expression requirements for dietary supplements in any jurisdiction and should be treated as a red flag.

---

Conclusion

The labeling compliance issues surrounding NAD+ supplements are, at their core, a matter of information transparency: precursor molecule type, actual input quantity, purity, batch-to-batch stability, manufacturing system certification status, and regulatory classification in the destination market — these dimensions together constitute a verifiable compliance picture.

Japan's Food Labeling Act provides a relatively mature framework, and the JHNFA GMP certification system provides a verifiable anchor at the manufacturing process level. However, neither substitutes for independent verification — by consumers or importers — of the regulations applicable in the destination country. The regulatory landscape continues to evolve, particularly regarding the status of NMN in the United States and the European Union. Readers should treat this paper as a structural reference framework and consult the most current official sources before making specific decisions.

Dietary supplements are not drugs. Any representation that equates supplement labeling compliance with health outcomes goes beyond what current scientific evidence and regulatory frameworks permit. Verifiable labeling transparency is the starting point — not the endpoint — of a consumer's independent assessment of product quality.